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Bad bedfellows – autonomic dysfunction, inflammation, and diabetes! Are they related?
How? Evidence suggests the activation of inflammatory cytokines like IL-6 and TNFα
in newly diagnosed type 2 diabetes and that the inflammatory change correlates with
abnormalities in sympathovagal balance. Dysfunction of the autonomic system predicts
cardiovascular risk and sudden death in patients with type 2 diabetes. It occurs in pre-
diabetes, providing opportunities for early intervention. The importance of recognizing
autonomic dysfunction as a predictor of morbidity and mortality with intensification of
treatment suggests that all patients with type 2 diabetes at onset, and those with type
1 diabetes after 5 years should be screened for autonomic imbalance. These tests can be
performed at the bedside with real time output of information – within the scope of the
practicing physician – facilitates diagnosis and allows the application of sound strategies
for management.The window of opportunity for aggressive control of all the traditional risk
factors for cardiovascular events or sudden death with intensification of therapy is with
short duration diabetes, the absence of cardiovascular disease, and a history of severe
hypoglycemic events. To this list we can now add autonomic dysfunction and neuropathy,
which have become the most powerful predictors of risk for mortality. It seems prudent
that practitioners should be encouraged to become familiar with this information and apply
risk stratification in clinical practice. After all, how difficult is it to ask patients “do you have
numb feet?” and to determine their heart rate variability – it could be lifesaving. Ultimately
methods to reset the hypothalamus and the inflammatory cascade are needed if we are
to impact the care of patients with this compendium of conditions.
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My mind sent a message to my hypothalamus, told it to release the
hormone CRF into the short vessels connecting my hypothalamus and
my pituitary gland. The CRF inspired my pituitary gland to dump the
hormone ACTH into my bloodstream. My pituitary had been making
and storing ACTH for just such an occasion, and nearer and nearer
the zeppelin came. And some of the ACTH in my bloodstream reached
the outer shell of my adrenal gland, which had been My adrenal gland
added the glucocorticoids to my bloodstream. They went all over my
body, changing glycogen into glucose. Glucose was muscle food. It
would help me fight like a wildcat or run like a deer.
Kurt Vonnegut, Jr., Breakfast of Champions, 1973
THE LINK BETWEEN AUTONOMIC FUNCTION AND
INFLAMMATION
There has been an increasing shift to consider that inflammation
is central to the pathogenesis of diabetes and its complications
including macrovascular disease and microvascular disease, but
the origin for the inflammation has not been clearly delineated.
While inflammation can cause extensive tissue damage and death
it is also essential in the protection of the host and is a defense
mechanism against trauma, infection, and stress amongst other
provocative agents. What controls this response to trauma and
infection has been the focus of energetic pursuits over the past
decade and has revealed a potential answer. The inflammatory
response is controlled by neural circuitry of the autonomic ner-
vous system. The afferent arc consists of nerves that sense the
injury and infection and this in turn activates a cholinergic anti-
inflammatory pathway that modulates the response and is the
potential target for future therapies of diabetes (Borovikova et al.,
2000; Tracey, 2009). The lymphoid organs of the immune system
are innervated by cholinergic, catecholaminergic, dopaminergic,
and peptidergic neurons and the neurotransmitters can interact
with immune cells and alter their level of function. For instance in
the non-obese diabetic (NOD) mouse (as animal model for type
1 diabetes) neurons surrounding the pancreatic beta cells are lost
before there is damage to the islet, and the loss of tonic inhibitory
signals contributes to the subsequent beta cell destruction (Sar-
avia and Homo-Delarche, 2003). In addition destruction of the
capsaicin sensitive nerve fibers of the pancreas protect the beta cell
from streptozotocin induced beta cell injury (Capsaicin and STZ;
Razavi et al., 2006). Thus it seems that to begin to understand the
role of the autonomic nervous system in its more complex role in
inflammation and autoimmunity one needs to delve further into
this complexity. Like St Thomas we need to probe deeper!
SYMPATHETIC AND PARASYMPATHETIC NERVOUS
SYSTEMS
Traditionally the organization of the physiologic control of auto-
nomic nervous system functions has relied upon the division into
two main branches, the sympathetic and parasympathetic nervous
systems (PNS). Stimulation of the sympathetic Brauch mediates
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physiologic responses of fight and flight that are manifest as
increases in heart rate (HR) and blood pressure (BP), mobilization
of needed energy stores, and heightened arousal. The major neuro-
transmitters are epinephrine, norepinephrine, and dopamine and
these neurotransmitters mediate cellular responses by interacting
with G-protein coupled adrenergic receptors (α1, α2, β1, β2, β3)
and dopaminergic receptors (D1, D2, D3). In contrast stimulation
of the PNS tends to produce effects which are in general opposite
to those of the sympathetic nervous system (SNS) such as slowing
of the HR, decreased cardiac contractility, and enhanced digestive
functions. The principal neurotransmitter acetylcholine interacts
with G-protein coupled muscarinic acetylcholine receptors M1–
M5 and nicotinic ligand–gated ion channels (termed neuronal
type 1-111 and muscle type 1V; Wess et al., 2007).
In addition, the systems are distinguished by unique anatomical
features. Parasympathetic neurons reside in the brainstem medulla
and sacral portions of the spinal cord and sympathetic neuronal
cell bodies in the thoracic and lumbar spinal cord. Presynaptic
myelinated axons are projected through cranial nerves and/or
spinal nerves to synapses located in ganglia. From these postsy-
naptic unmyelinated fibers are derived, which themselves target
the innervated organ. It is also important to realize that although
at first glance these systems appear to have opposing effects, e.g.,
sympathetic increases HR and parasympathetic slows HR, stim-
ulation of both results in a greater increase in cardiac output
because sympathetic stimulation increases the ejection fraction
and parasympathetic stimulation slows the heart, thus allow-
ing increased efficiency of cardiac filling. Similarly, baroreceptors
which perceive stretch in the aorta with increasing BP send sig-
nals via the sensory component of the vagus terminating in the
nucleus of the tractus solitarius in the medulla. From here presy-
naptic fibers of the SNS project to the ventrolateral nucleus of
the medulla and parasympathetic presynaptic neurons to nucleus
ambiguous in the medulla. Coordinated firing of both arms of
the autonomic nervous system is necessary to respond to changes
in BP and, if damage occurs, is reset to accommodate new levels
which may be too high or too low for the individual. Thus, one
needs to consider the system in its entirety. Damage to one or
another component may not have as devastating an effect as dam-
age to the whole system. Within this framework Figure 1 illustrates
the entire workings of the autonomic nervous system.
AUTONOMIC NERVOUS SYSTEM CONTROL OF
INFLAMMATION
Watkins et al. (1995) discovered that sensory neurons detect the
presence of inflammation in tissues (Figure 2). These responses to
IL-1 induced inflammation were mediated by the vagus, and could
be abolished by vagotomy or a selective competitive antagonist of
the IL-1 receptor (Goehler et al., 1997; Hansen et al., 2001). In
cardiovascular physiology, oxygen, glucose, and other metabolites
are sensed by specialized glomus cells in the association with the
nervous system. Upon activation, these cells release dopamine and
norepinephrine causing depolarization of the sensory fibers in the
vagus which propagate to the brainstem and initiate a motor effer-
ent arc. It appears that IL-1 binds to the glomus cells initiating the
afferent arc; however there are a number of other ligands derived
from macrophages, monocytes, and dendritic cells referred to as
pathogen-associated molecular patterns (PAMPS) which activate
Toll-like receptors (TLR) and lead to increased expression of NF-
κB and increased release of inflammatory cytokines such as TNF-a
and IL-6. Endogenous molecular products are also released from
damaged cells and are referred to as damage associated molecular
patterns (DAMPS). Thus the nervous system is capable of initiat-
ing a response to tissue injury and inflammation and can per se
initiate a pro-inflammatory response. One must therefore add a
neuro-regulatory role for the autonomic nervous system to the
one outlined above.
The efferent arc of this inflammatory response is termed
the cholinergic anti-inflammatory pathway. The neurotransmitter
acetylcholine interacts with the innate immune cells that express
the nicotinic acetylcholine receptor subunit α7 (α7nAChR). The
receptor is widely expressed in neurons which function as ligand-
gated ion channels encoded by CHRNA 7 on chromosome 15q14
and is a product of 10 exons yielding a mature protein of 50kDa.
α7nAChR has a tonic inhibitory role in the immune cells simi-
lar to the effects of the parasympathetic system on inhibition of
HR. Exaggerated responses to inflammatory molecules are caused
by vagotomy, whereas stimulation of the vagus downregulates
the production of TNFα, IL-1, IL-6, and IL-8but does not alter
the anti-inflammatory cytokine IL-10 and TGFβ. This ACh acti-
vates the JAK/STAT pathway, affecting the inflammatory responses
mediated by NF-kB and initiating the release of a variety of inflam-
matory cytokines. Thus this is a defensive reflex protecting the
organism from organ damage and death when exposed to syn-
dromes of excess cytokine release such as infection, trauma, and
stress.
DIABETES – A STATE OF FAULTY SYMPATHETIC BALANCE
AND CHRONIC INFLAMMATION
We have hypothesized that in the metabolic syndrome and diabetes
there is a constant increase in low grade inflammation mediated
by a large cadre of exogenous and endogenous ligands (Figure 3).
These in turn are capable of binding to the advanced glycation
end product receptor (RAGE) and thereby activating NF-kB path-
way and increasing the production of inflammatory cytokines. In
addition there are a number of other ligands capable of activat-
ing the inflammatory cascade. DAMPS for example, can stimulate
innate immune responses culminating in NF-kB activation as with
the ligands for RAGE. This is further compounded by the ligands
binding to the TLR which potentiate the activation of NF-kB. The
balance occurs by binding of acetylcholine to the α7nACHR recep-
tor and via JAK2 and Stat restraining the activation of NF-kB. Thus
the loss of autonomic control with reduction of parasympathetic
activity, hallmark autonomic dysfunction in diabetes, initiates a
cascade of inflammatory responses that, if continued unabated
will culminate in considerable morbidity and mortality. The pos-
sible approaches to enhancing parasympathetic function will be
discussed below.
THE CONSEQUENCE OF AUTONOMIC DYSFUNCTION IN
DIABETES
Cardiac autonomic neuropathy (CAN) and sympathetic/
parasympathetic imbalance is a significant cause of morbidity and
mortality associated with a high risk of cardiac arrhythmias and
Frontiers in Endocrinology | Diabetes June 2012 | Volume 3 | Article 71 | 2
Vinik Autonomic function
FIGURE 1 | A diagrammatic illustration of the role of the two arms of the
autonomic nervous system. Note that in general the actions of the
sympathetic nervous system are illustrated as being in the opposite direction
to that of the parasympathetic nervous system. Not shown here but
discussed below is the CNS regulation of the immune system via the vagal
cholinergic anti-inflammatory pathway adding yet another dimension to the
role of the autonomic nervous system in survival of the organism. Note that
Kurt Vonnegut recognized the importance of the CNS in stress but failed to
recognize its role as the conductor of the endocrine and autonomic orchestra.
But then he was not a biologist!
sudden death, possibly related to silent myocardial ischemia. The
prevalence of CAN may be high. In a large cohort of patients with
T2DM, Ziegler et al. (1995), using predefined heart rate variability
(HRV) and spectral analysis of the R–R intervals, found that 34.3%
of those with T2DM had abnormal findings. Newly diagnosed
type 2 diabetes (Lieb et al., 2011) and prediabetes stages [(i.e.,
impaired glucose tolerance (IGT)] are associated with a decreased
parasympathetic modulation of the heart and a shift toward aug-
mented sympathetic tone. Factors that influence the prevalence
of CAN include the diagnostic criteria used, patient age, and the
duration of diabetes (Vinik and Ziegler, 2007). Additional clinical
correlates and predictors of CAN include glycemic control; pres-
ence of distal peripheral neuropathy (DPN), nephropathy, and
retinopathy; BP levels, obesity; smoking; cholesterol; and triglyc-
erides levels (Vinik and Ziegler, 2007). Additional factors which
emerged as identifying susceptibility to cardiovascular events with
intensification of glycemic control included: duration of diabetes
>12–15 years, impaired renal function, coronary artery calcifica-
tion, a previous cardiovascular event, being African American,
being female, aging, a history of neuropathy or numb feet, and
loss in HRV (Calles-Escandon et al., 2010; Pop-Busui et al., 2010;
Vinik et al., 2011). Parasympathetic tone may decline with an auto-
nomic imbalance shifting toward augmented sympathetic tone
during the development from normal glucose tolerance to IGT
and finally diabetes (Wu et al., 2007).
MORBIDITY AND MORTALITY IN CARDIAC AUTONOMIC
NEUROPATHY
Cardiac autonomic neuropathy defined by measures of abnor-
malities in PNS and SNS, is a significant cause of morbidity
and mortality associated with a high risk of cardiac arrhythmias
and sudden death, possibly related to silent myocardial ischemia.
Cardiovascular disease (CVD) remains the main cause of excess
mortality among patients with type1 (T1DM) and type 2 dia-
betes (T2DM). The prevalence of CAN varies greatly depending
on the criteria used to identify CAN as well as the population
studied. These range from as low as 2.5% of the primary pre-
vention cohort in the Diabetes Control and Complications Trial
(DCCT, 1998) to as high as 90% of patients with long-standing
T1DM who were potential candidates for a pancreas transplant
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FIGURE 2 | Afferent sensory signals are transmitted by the vagus to the
nucleus of the solitary tract (NTS) and polysynaptic receptors relay to
the sympathetic via the rostral ventromedullary nucleus (RVLS) and the
parasympathetic nucleus ambiguous (NA and the dorsal vagal nucleus.
There is both sympathetic and parasympathetic output to the celiac ganglion
and the splenic nerve activates the inflammatory cascade in macrophages
which may be in the spleen but occur diffusely throughout the body.
Stimulation of the vagus inhibits this activation by acetylcholine binding to the
α7nACHR receptor which curtails the response. Also shown is the
coactivation of the hypothalamic pituitary axis with release of glucocorticoids
which also modulate the inflammatory response. It is however unclear how
this set point is determined in the body but what is clear is that autonomic
modulation of inflammation can be achieved by altering
sympathetic/parasympathetic balance.
(Kennedy et al., 1995). In a large cohort of patients with T1DM and
T2DM, Ziegler et al. (1995), using predefined HRV and spectral
analysis of the R–R intervals, found that 25.3% of patients with
T1DM and 34.3% of those with T2DM had abnormal findings.
Even the prediabetic stage (i.e., IGT) is associated with a decreased
parasympathetic modulation of the heart and a shift toward aug-
mented sympathetic tone. Parasympathetic tone may decline with
an autonomic imbalance shifting toward augmented sympathetic
tone during the development from normal glucose tolerance to
IGT and finally diabetes (Wu et al., 2007). Reduced HRV as a
marker of autonomic dysfunction has been shown to have dire
consequences in terms of morbidity (e.g., progression of coronary
atherosclerosis; Huikuri et al., 1999), and mortality independent
of cardiovascular risk factors (La Rovere et al., 2003; Maser et al.,
2003; Hadase et al., 2004; Janszky et al., 2004) in various popula-
tions including those with prediabetes and diabetes (Ziegler et al.,
2008; Beijers et al., 2009). In T1DM there is a fourfold increased
risk of death (Orchard et al., 1996). CAN is significantly associated
with overall mortality (Maser et al., 2003; Vinik et al., 2010) and in
some – but not all – studies with morbidity such as silent myocar-
dial ischemia, coronary artery disease, stroke, diabetic nephropa-
thy progression, and perioperative morbidity. Some pathogenetic
mechanisms may link CAN to cardiovascular dysfunction and dia-
betic complications (Vinik et al., 2011). Thus, CAN assessment
may be used for cardiovascular risk stratification in patients with
and without established CVD; as a marker for patients requiring
more intensive monitoring during the perioperative period and
other physiological stresses; and as an indicator for more inten-
sive pharmacotherapeutic and lifestyle management of comorbid
conditions. Clearly the role of autonomic imbalance and the mech-
anisms underlying the risk require further exploration if we are to
achieve benefit for all. However foremost in our minds is the issue
of why diagnose if we cannot treat?
CONSEQUENCES OF AGE/RAGE INTERACTIONS IN DIABETES
Hyperglycemia increases protein glycation and causes a gradual
accumulation of advanced glycation end products (AGEs) in body
tissues. These AGEs form on intra- and extra-cellular proteins,
lipids, and nucleic acids, in complex arrangements that lead to
cross-linking. It has also been shown that an accumulation of
AGEs in collagen tissue such as skin, measured by skin autoflu-
orescence, correlates with severity of peripheral and autonomic
nerve abnormalities in diabetes, even before being clinically man-
ifest (Meerwaldt et al., 2005). Both immunohistochemical and
biochemical studies have shown that carboxymethyllysine (CML)-
modified proteins are AGEs that accumulate in tissues affected by
diabetic complications, such as bone. This process is mediated
through RAGE, the pattern recognition receptor for AGE. Of the
three known receptors for AGE, RAGE is of particular interest
because it is found on many cell types, especially those affected
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FIGURE 3 |The relationship between binding of ligands to the pattern
recognition AGE receptor (RAGE) and inflammation, gene expression,
oxidative and nitrosative stress, and damage to the macro- and
microvasculature. Elevated levels of glucose bind to proteins and form
AGEs, which bind to RAGEs. RAGE signaling activates NADPH oxidase and
production of reactive oxygen species (ROS). Increased ROS increases
advanced oxidation protein products (AOPPs), more AGEs, and
AGE-modification of oxidized LDLs (oxLDLs). Furthermore, increased ROS
may deplete glutathione, thereby suppressing glyoxalase I activity, a
mechanism favoring further AGE accumulation. AGEs, AOPPs, macrophage
glycoprotein (MAC-1), and AGE-oxLDL ligands of RAGE sustain stimulation of
RAGE, and these processes, together with increased ROS, activate key
transcription factors such as nuclear factor-κB (NF-κB) and Egr-1, which
increase gene transcription factors and activate inflammatory mechanisms.
Consequences include increased migration and activation of RAGE-expressing
neutrophils, monocytes/macrophages, T-cells, and dendritic cells. This results
in the release of the pro-inflammatory RAGE ligands S100/calgranulins and
high-mobility group protein box-1 (HMGB1). In this inflammatory
environment, further AGEs may be formed as well. Via interaction with RAGE,
these ligands magnify activation of NF-κB, Agr-1, and other factors, thereby
amplifying cellular stress and tissue damage leading to neurovascular
dysfunction. Soluble RAGE (sRAGE) is formed from the cleavage of RAGE by
disintegrins such as ADAM 10, a metalloproteinase, and β- and γ-secretases.
sRAGE or a spliced variant (esRAGE) compete for binding of ligands to RAGE,
and a deficiency could theoretically initiate the sequence of events activating
an inflammatory cascade with an increase in the expression of
pro-inflammatory cytokines [E-selectin, endothelin-1 tissue factor, vascular
endothelial growth factor, and other pro-inflammatory cytokines (interleukin-6
and tumor necrosis factor-α)] and damage to neurons, kidney, eye, the
vasculature, and even bone. Increasing sRAGE or its administration could
competitively reduce activation of the AGE/RAGE pathway and it
consequences. In addition endogenous and exogenous ligands bind to Toll-like
receptors (TLR) also targeting NF-KB as well as inducing the secretion of
pro-inflammatory cytokines which activate afferent sensory neurons reaching
the brainstem via axons in the vagus. This in turn activates the cholinergic
anti-inflammatory efferent arc which inhibits response in cytokine producing
immune cells and signal through the nicotinic acetylcholine receptor subunit
α7 (α7nACHR). This in turn inhibits NF-κB activation. Thus the pathways of
AGE/RAGE activation of the inflammatory cascade and the inflammatory
ligands target activation of an inflammatory cascade that can be abrogated by
either competing with the binding of ligands to RAGE or by vagal activation of
the anti-inflammatory reflex. Thus central to curtailing unbridled activation of
the inflammatory cascade is the integrity of parasympathetic autonomic
function or balance between the two arms of the autonomic nervous system.
by diabetes. RAGE is constitutively expressed but is also induced
by reactions known to initiate inflammation. Patients with dia-
betes often display elevated CML levels that can bind and activate
RAGE signaling (Schmidt et al., 2001). Furthermore, AGE-RAGE
interaction creates a chronic cascade of inflammation and tissue
injury. Of further interest, RAGE knockout mice have a reduced
capacity to develop neuropathy (Toth et al., 2008; Takuma et al.,
2009), and the soluble form of the AGE receptor sRAGE, can act
as a decoy molecule, thereby reducing the binding of ligands to
RAGE and inhibiting the inflammatory cascade (Figure 3). Our
studies in Charcot neuroarthropathy show the presence of severe
somatic and autonomic neuropathy in association with reduced
levels of sRAGE (Witzke et al., 2011) (Table 1).
In homeostasis, RAGE is expressed at low levels but during bio-
logical stresses such as inflammation and diabetes, RAGE expres-
sion is greatly upregulated as a direct result of AGE accumulation.
Many studies have now shown that AGE-RAGE interactions alter
intracellular signaling via pro-inflammatory cytokines such as
IL-6, TNF-α, and free radicals that further propagate diabetic com-
plications. Interestingly the two pathways, autonomic function
and inflammation may be linked since it has become evident that
autonomic dysfunction is associated with an increase in circulating
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Table 1 | Peripheral and autonomic nerve dysfunction and reduction of sRAGE in diabetes and Charcot neuroarthropathy (mean ± SD).
Control (n=30) Diabetes (n=30) Charcot (n=20)
Tibia-ankle
Amplitude 8.9±4.1 4.3±3.8* 0.6±1.0†
Latency 4.7±0.7 4.2±1.8 3.6±5.5
Conduction velocity 45.4±3.7 35.4±15.2* 7.7±13.1†
F-wave 54.7±6.4 47.5±23.3 17.5±29.7†
Sural Response (number with positive response) 30 28 4
Vibration perception (µ) 10.6±11.1 31.7±27.3* 100.5±31.5†
Pressure perception (g) 2.9±0.4 3.1±0.3 5.9±1.2†
Cold sensation (ºC) 5.5±2.7 7.7±5.2 20.9±9.9†
Warm sensation (ºC) 7.1±3.1 10.3±3.2* 14.9±3.2†
Cold pain 24.5±9.0 26.4±6.6 30.6±3.5†
Warm pain 14.0±3.3 15.4±2.5* 17.5±1.0†
Valsalva ratio 1.43±0.25 1.36±0.31 1.18±0.28†
Parasympathetic deep breathing 611±13 617±13 632±18†
Sympathetic Valsalva response 714±17 713±16 717±20
N telopeptide (NTx; nmol/L) 13.6±5.5 11.4±5.7 13.8±8.2
Osteocalcin (ng/mL) 1.29±0.96 1.23±5.7 2.29±2.57*
sRAGE (pg/mL) 1140±471 522±660‡ 162±67*
Bone mass density (BMD; g/cm2)
Femoral neck 1.004±0.141 1.048±0.184‡ 0.904±0.219
Greater trochanter 1.080±0.157 1.116±0.165‡ 0.987±0.185
Total hip 1.018±0.129 1.037±0.150 0.955±0.252
Foot 0.754±0.081 0.792±0.105 0.788±0.120
Calcaneal stiffness index 105.2±14.0 103.3±18.6 77.1±26.2*
Continuous data are expressed as mean ± SD; categoric data as n. *p<0.05 vs control subjects. † p<0.05 vs diabetic and control subjects. ‡ p<0.05 vs Charcot
subjects (Witzke et al., 2011) with permission.
inflammatory cytokines (Lieb et al., 2011). Furthermore, recent
studies support the notion that autonomic reflexes may control
the inflammatory response (Tracey, 2009).
CARDIOVASCULAR AUTONOMIC BALANCE
Autonomic balance involves complex interactions with several
physiologic mechanisms that act to maintain HR and BP within
normal limits. Recent investigations have suggested that auto-
nomic dysfunction (e.g., heightened activity of the SNS and sup-
pressed activity of the PNS) impairs the ability of the ANS to
regulate the cardiovascular system. Thus, autonomic imbalance
may be a key component involved in both the etiology and the
clinical course of CVD. What is also emerging is that one needs to
distinguish the difference between autonomic imbalance and clear
evidence of autonomic neuropathy. Autonomic imbalance pro-
duces a number of interesting and trying clinical situations such
as orthostatic tachycardia, orthostatic bradycardia, and hypoten-
sion and can be responsible for predisposition to arrhythmias and
sudden death (Vinik et al., 2011). The most interesting implica-
tion of loss of autonomic imbalance derives from the catastrophic
increase of sudden death in the ACCORD study with intensive
lowering of blood glucose in which the combination of numbness
of the feet and loss of HR variability increased the susceptibility
to an event with a risk ratio (RR) of 4.43 (Calles-Escandon et al.,
2010; Vinik et al., 2011). Most recently an International Group has
updated definitions of diabetic neuropathy including autonomic
neuropathy and reported upon these (Tesfaye et al., 2010).
CARDIAC AUTONOMIC ASSESSMENT
Cardiovascular reflex tests are the gold standard in clinical auto-
nomic testing. These tests have good sensitivity, specificity, and
reproducibility and are non-invasive, safe, well-standardized, and
easily performed (Vinik and Ziegler, 2007). The most widely used
tests assessing cardiac parasympathetic function are based on the
time-domain HR response to deep breathing, a Valsalva maneu-
ver, and postural change. However, a Valsalva maneuver must not
be performed in patients with proliferative retinopathy. Of these
tests, HR to deep breathing has the greatest specificity (−80%).
Cardiovascular sympathetic function is assessed by measuring the
BP response to orthostatic change and a Valsalva maneuver. The
performance of these tests should be standardized, and the influ-
ence of confounding variables such as medications, hydration, and
antecedent activity should be minimized. Age normative values
should be used. The combination of cardiovascular autonomic
tests with sudomotor function tests may allow a more accurate
diagnosis of diabetic autonomic neuropathy (DAN), but this is
still in the research arena.
Analysis of HRV is a non-invasive electrocardiographic method
for assessing overall autonomic activity (Malik and the Task Force
of the European Society of Cardiology and the North American
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Society of Pacing and Electrophysiology, 1996). Analysis of HRV,
with analysis of respiratory activity, independently and simultane-
ously measures parasympathetic and sympathetic activity (Aksel-
rod et al., 1981), and thereby provides information with regard
to autonomic balance of the cardiovascular system. Power spec-
tral analysis of HRV can be performed under resting conditions
with demonstration of low-frequency (LF) and high-frequency
(HF) components. The LF component of the power spectrum of
HRV primarily reflects sympathetic activity, while the HF compo-
nent (also termed the respiratory-frequency, RF) primarily reflects
parasympathetic activity. LF/RF ratios are calculated and provide a
measure of sympathetic/parasympathetic activity. The total spec-
tral power (TSP) is calculated, as are the standard deviation of
all normal R–R intervals (sdNN; a measure of both sympathetic
and parasympathetic action on HRV) and the root-mean square
of the difference of successive R–R intervals (rmSSD), a measure
primarily of parasympathetic activity (Vinik and Ziegler, 2007).
Diabetic patients with features of cardiac autonomic dysfunc-
tion such as unexplained tachycardia, orthostatic hypotension, and
poor exercise tolerance, or with other symptoms of autonomic
dysfunction should be evaluated for the presence of autonomic
dysfunction. Screening for autonomic dysfunction should be per-
formed at the diagnosis of type 2 diabetes and 5 years after the
diagnosis of type 1 diabetes, particularly in patients at greater
risk due to a history of poor glycemic control, cardiovascular risk
factors, DPN, and macro- or microangiopathic diabetic complica-
tions. While a number of tests for autonomic dysfunction are in
the research arena some have been shown to be sufficiently robust
to be incorporated into routine clinical care (Tesfaye et al., 2010;
Spallone et al., 2011) (Table 2).
CAN TESTING FOR CLINICAL TRIALS AND RESEARCH
The time-domain HR tests and the BP response to postural change
have the reproducibility necessary for clinical trials. These tests
were used as end points in the Diabetes Control and Complications
Trial/Epidemiology of Diabetes Interventions and Complications
Study (DCCT EDIC Research Group, 2005) and other clinical
trials.
Frequency-domain indices obtained by applying spectral analy-
sis to HR variability of short (5–7 min) and long (24-h) elec-
trocardiogram recordings provide a measure of sympathetic and
parasympathetic modulation of HR as described before. HR spec-
tral power in the HF region is a measure of parasympathetic mod-
ulation, while spectral power in the LF region provides a measure
of both sympathetic and parasympathetic modulation. The LF BP
variability may provide a measure of sympathetic modulation. To
correctly assess the significance of the different regions, respiration
should be measured or controlled breathing performed. These
methods, which need standardization, have been widely used in
research and as end points in clinical trials. These have now been
shown to be invaluable in patients with clinical syndromes of auto-
nomic excess or deficiency and can be accomplished in 15 min at
the bedside without need to resort to more complex studies using
tilt table testing, for example. In addition it is a sound general rule
that an autonomic function test becomes useful when suspecting
autonomic nerve dysfunction (gastroparesis, erectile dysfunction
or diabetic diarrhea, and syncope amongst other conditions). A
negative test has >95% negative predictive value for autonomic
dysfunction and becomes the relatively simple surrogate for more
expensive, complex, and at times invasive tests (Figure 4).
TREATMENT OF AUTONOMIC DYSFUNCTION
TARGETING INFLAMMATION
The treatment of inflammatory diseases including chronic inflam-
matory demyelinating polyneuropathy (CIDP) and autonomic
neuropathy has had a significant boost by the use of immunoglob-
ulin, and biological agents that modulate the activity of TNF-a,
IL-1, and IL-6 (Pittenger et al., 1997; Vinik et al., 2006b; Ananda-
coomaraswamy et al., 2008; Bourcier andVinik, 2010; Handelsman
et al., 2011). These agents have been shown to ameliorate rheuma-
toid arthritis and inflammatory bowel disease, which is what
serendipitously directed us to the use of an anti-TNFα in dia-
betic neuropathies. They are, however, potentially harmful as they
are immunosuppressants and a more benign intervention is clearly
necessary. For example, electrical stimulation of the vagus nerve or
administration of the a7nACHR agonists reduces the magnitude
FIGURE 4 | Spectral analysis of heart rate variability.
Table 2 | Cardiovascular autonomic tests and suggested indications for their use.
Clinical diagnosis Research end point Clinical trials
HR cardiovascular tests Yes Yes Yes
Orthostatic hypotension test Yes Yes No (low sensitivity)
QT interval Yes (additional information and risk stratification) Yes No (low sensitivity)
ABPM for dipping status Yes (risk stratification) Yes No (low sensitivity)
HRV time- and frequency-domain indices Yes (early additional information and risk stratification) Yes Yes
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of the inflammatory response by 50–75% without compromising
cytokine activity (Borovikova et al., 2000; Bernik et al., 2002; Saeed
et al., 2005; Huston et al., 2006). Depressed vagal activity or the loss
of sympathovagal balance has been shown to cause exaggerated
pro-inflammatory responses and increased morbidity and mor-
tality (Thayer and Sternberg, 2006; Thayer and Fischer, 2009).
Vagus nerve activity can be measured in humans by time and
frequency-domain analysis of instantaneous HRV in the resting
state as well as with provocative testing of the effects of vagal stim-
ulation using the respiratory variation, the Valsalva maneuver, and
the effects of standing (Vinik and Ziegler, 2007). Also, peripheral
vagal activity can be measured using the pancreatic polypeptide
response to insulin hypoglycemia or beef meals (Glaser et al.,
1980), and peripheral preganglionic measures of acetylcholine
effects on sweating can be determined using sudorimetry, and
quantitative sudorimetry (Low et al., 1983; Vinik and Ziegler,
2007).
Indeed in our studies of the regulation of skin blood flow we
have shown that there are major differences in the autonomic
regulation of blood flow in hairy skin of the forearm, which is
almost entirely dependent on sympathetic/parasympathetic con-
trol (Vinik et al., 2006a). By contrast in glabrous skin there is a
dependence on vasodilatory peptides such as CGRP and Neu-
rokinin A as well as certain vasodilatory and vasoconstrictive
prostaglandins (Vinik and Kles, 2006). In rheumatoid arthri-
tis high-frequency oscillation which reflect vagal activity are
depressed compared with healthy controls (Pontet et al., 2003).
Pontet and colleagues evaluated the effects of HRV on the crit-
ical care setting in patients with sepsis a low HRV is associated
with organ failure whereas subjects with a normal HRV had
uneventful hospital stays (Pontet et al., 2003). The mortality rate
of individuals with low HRV on admission was 63.6% com-
pared with 0% in the group with normal HRV (Pontet et al.,
2003). Of greater interest is the association between atheroma
and reduced HRV (Hanson and Libby, 2006; von Kanel et al.,
2008).
THERAPEUTIC IMPLICATIONS OF ALTERING AUTONOMIC BALANCE
We (Lieb et al., 2011) examined patients with newly diagnosed
diabetes, established diabetes, and healthy controls and analyzed a
cadre of inflammatory markers in addition to time and frequency-
domain measures of autonomic function. Of great interest to us is
the appearance before the advent of inflammation of loss of HRV
as well as loss of sympathetic/parasympathetic balance (Figure 5;
Table 3). Early in the development of autonomic dysfunction there
is loss of HRV and this correlates with an increase in circulating
markers of inflammation such as CRP and IL-6 (Lieb et al., 2011).
Analysis of 102 healthy middle aged individuals found an
association between loss in HRV and IL-6 levels. The authors
concluded that low grade inflammation is associated with loss
in HRV (von Kanel et al., 2008). Another study on 611 healthy
adults showed an inverse correlation between HRV and CRP lev-
els. The authors concluded that the effect could be attributed to low
grade inflammation due to a decrease in the cholinergic pathway
of anti-inflammatory cascades with implications for addressing
inflammation in the prevention and management of heart dis-
eases (Thayer and Fischer, 2009). HRV, CRP, and IL-6 levels were
measured in 757 young adults and HRV was significantly related
to IL-6 and CRP levels which was thought to be consistent with
the notion that the cholinergic anti-inflammatory pathways exert
a tonic inhibitory influence on innate immune responses and
could be the potential target for future interventions. Of particular
note is the sequence of events shown in Figure 5 suggesting that
circulating adiponectin (HMW) and leptin levels may be early pre-
dictive markers, and the mechanism may be via insulin resistance
or direct actions of Leptin on the hypothalamus and the autonomic
nervous system. In our study, we found that newly diagnosed dia-
betic subjects had significantly lower HMW adiponectin/leptin
ratios when compared with control subjects, and saw significant
correlations between the HMWA/leptin ratio and multiple mea-
sures of autonomic function (LFa/RFa ratio, TSP baseline, and
rmSSD baseline) (Lieb et al., 2011). In a study of 120 non-obese
humans without diabetes, Paolisso et al. (2000) demonstrated
FIGURE 5 |The natural history of autonomic balance.
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Table 3 | Measures of autonomic function and inflammation in healthy controls, newly diagnosed and established diabetes.
Measure Controls (n=15) Newly diagnosedT2D (n=15) EstablishedT2D (n=15) p value
R–R ratio (deep breathing) 1.26±0.04 1.20±0.03 1.17±0.05 0.0325#
R–R ratio (Valsalva) 1.58±0.21 1.37±0.06 1.24±0.05 0.0270*
R–R ratio (standing) 1.29±0.04 1.26±0.05 1.18±0.02 NS
LFa 1.60±0.43 1.90±0.39 1.37±0.37 NS
RFa 1.21±0.27 1.89±0.79 0.73±0.29 NS
LFa/RFa ratio 1.53±0.24 2.51±0.51 2.88±0.56 NS
TSP baseline 950.88±191.95 772.94±290.95 416.95±142.61 0.0023*
sdNN baseline 47.66±4.87 41.04±3.92 28.92±4.65 0.0008*
rmSSD baseline 30.18±3.76 28.77±6.97 18.97±3.38 0.0356#
IL-6 (pg/mL) 2.84±0.68 (n=14) 11.58±2.83 12.04±1.20 (n=12) <0.0001#
TNF-α (pg/mL) 9.32±2.18 (n=14) 9.14±1.15 27.93±15.4 (n=12) NS
PAI-1 (ng/mL) 3.05±0.56 5.23±0.76 6.41±1.36 0.0305*
Total adiponectin (mg/mL) 6.76±0.78 7.48±1.11 8.91±2.3 NS
High-molecular weight adiponectin (µg/mL) 1.78±0.26 2.33±0.60 2.71±1.54 NS
Leptin (ng/mL) 28.66±7.93 46.87±7.96 55.93±11.39 NS
TA/L ratio 1.17±0.76 0.24±0.05 0.53±0.32 0.0340*
HMWA/L ratio 0.49±0.40 0.07±0.02 0.26±0.22 0.0442#
Modified from Lieb et al. (2011).
Data are presented as means ± SE. NS, not significant. *Established T2D vs controls/newly diagnosed T2D.
#Newly diagnosed/established T2D vs controls.
TSP, total spectral power; SDNN, standard deviation of all normal R–R intervals; rmSSD, root-mean square of the difference of successive R–R intervals.
IL-6, interleukin-6; TNFα, tumor necrosis factor alpha; PAI, plasminogen activator Inhibitor 1; TA/L, total adiponectin/leptin ratio; HMWA/L, high-molecular weight
adiponectin/leptin ratio.
that increasing plasma leptin concentrations were associated with
increasing LFa/HFa ratios, suggesting greater SNS activity as com-
pared with PSN activity. Studies have also shown interesting
correlations between adiponectin and autonomic function. Wak-
abayashi and Aso (2004) studied 105 men and women with T2D
and found that adiponectin concentrations correlated negatively
with the LFa/RFa ratio. Of note, changes in the adiponectin/leptin
balance in the course of diabetes may first be seen by utilizing
measures of high-molecular weight adiponectin rather than total
adiponectin, as demonstrated by our findings (Table 3). These
findings and the results in animal studies again suggest that the
effects on adipose tissue cytokine release may be a consequence
of autonomic dysfunction as opposed to the corollary. Clearly a
closer look at the relationship between adipose tissue cytokines,
obesity, and the impact of weight reduction on the relationship
between inflammation and HRV is warranted. With the explosive
developments in global obesity and the proliferation of gastric
bypass procedures on adults and even children, no doubt this
will yield a fertile field for exploring these relationships and their
potential for therapeutic intervention.
RESTORING AUTONOMIC BALANCE
Physiological health is characterized by organized variability in
organ functions which are controlled by neural networks that
provide compensatory output to maintain homeostasis around
set points which are appropriate for the system in time, gender,
age, body weight, and BP among other variables such as exercise,
sedentary habits, and smoking. While these neural network imbal-
ances can theoretically be corrected by relatively simple maneuvers
they are in general difficult to obtain and maintain. However this
is possible. Our interest in falling and fractures in older diabet-
ics has taught us that much of these injuries are due to the loss
of the organized variability, strength, and reaction times; further-
more, with very simple strength and balance training falls risk
can be significantly reduced (Morrison et al., 2010). Just as when
landing planes in Hong Kong the pilot indulges in serial deviations
in wing tip position to allow the computer to correct these and
ensure a safe landing we have a need to enhance the imbalance in
autonomic and inflammatory reflexes that characterize the loss of
physiological and pathological flexibility. Just as in diabetes man-
agement, this requires work and of course we all want the magic
bullet. Some are on the horizon. However, even simple maneuvers
such as walking the dog can restore autonomic balance (Figure 6).
For the abnormalities in autonomic balance adrenergic excess can
be addressed with beta blockers and parasympathetic excess with
anticholinergic drugs (Vinik and Erbas, 2006; Table 4).
REVERSIBILITY OF AUTONOMIC IMBALANCE
We have reported simple pharmacological manipulation of situa-
tions of parasympathetic and sympathetic imbalance with impor-
tant changes in the symptom complex and quality of life of the
afflicted individuals (Vinik et al., 2011). Intervention studies have
documented the protective effects of glycemic control in type 1
diabetes (DCCT) and of multifactorial strategy aimed at lifestyle
change with pharmacological correction of hyperglycemia, hyper-
tension, dyslipidemia, and microalbuminuria (Gaede et al., 2003).
Immune therapy for patients with antibodies to the ACH recep-
tor has been effective in relieving postural hypotension (Bourcier
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FIGURE 6 |The effects of walking with and without a pet dog, on
parasympathetic function (mean high frequency power). (A) 80-min
walking programme including two 30-min walks without and with the dog
(n = 13). (B) 80-min walking programme over three consecutive days (n=3).
(C) Interaction with the dog at home during 6 h of continuous monitoring
(n = 4).
Table 4 | Diagnosis and management of autonomic dysfunction.
Symptoms Assessment Modalities Management
Resting tachycardia, exercise intolerance, early
fatigue, and weakness with exercise
HRV, respiratory HRV, MUGA thallium
scan, 123I MIBG scan
Graded supervised exercise, beta blockers,
ACE-inhibitors
Postural hypotension, dizziness, lightheadedness,
weakness, fatigue, syncope, tachycardia/bradycardia
HRV, blood pressure measurement
lying, and standing
Mechanical measures, clonidine, midodrine,
octreotide, erythropoietin, pyridostigmine
Hyperhidrosis Sympathetic/parasympathetic balance Clonidine, amitryptylline, trihexyphenidyle,
propantheline, or scopolamine, botox, glycopyrrolate
and Vinik, 2010). Antioxidant therapy with alpha lipoic acid
restores autonomic function toward normal (Ziegler et al., 2011).
More recently interest in the selective muscarinic acetylcholine
receptor has been shown to suppress innate immune responses in
the periphery by increasing the firing rate of action potential in
the vagus (Pavlov et al., 2007). To quote “The end products of a
search for agents with which to restore balance will be a map of the
homunculus of sensory and motor components corresponding to
neuroanatomical and functional neurophysiologic pathways link-
ing the autonomic and inflammatory pathways and their response
to endogenous as well as exogenous stressors of the system.”While
Kurt Vonnegut had insights in Breakfast of Champions in 1973 it
is only now that this link is gaining recognition for the havoc
it wreaks and the potential for avoidance and therapeutic inter-
vention. Of great interest are the abnormalities in the diurnal
regulation of dopaminergic tone. In type 2 diabetes a reduction
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in dopaminergic tone in the early morning results in increased
hepatic gluconeogenesis, a rise in circulating free fatty acids,
resistance to the action of insulin, increases in markers of inflam-
mation and hypercoagulation, all of which can be restored toward
normality by treatment with a dopaminergic agonist (Scranton
et al., 2007) which reverses the metabolic abnormalities simply by
enhancing parasympathetic dominance. There are simple maneu-
vers to improve HRV as shown by Motooka et al. (2006). Little old
ladies walking the dog have enhanced parasympathetic function.
Removing the dog is enough to incite sympathetic overactivity. We
have shown that balance can be adjusted with agents that act on
one or other arm of the autonomic nervous system (Vinik et al.,
2011; Figure 7)
Gaede in the Steno memorial study (Gaede et al., 1999, 2008)
showed that a multifactorial intervention controlling BP, lipids,
and hyperglycemia reduces abnormalities in autonomic func-
tion by 68%, and Ziegler et al. (1997) report that alpha lipoic
acid improves autonomic function. In fact, it is one of the only
drugs targeting the nervous system to be endorsed by the Toronto
consensus (Tesfaye et al., 2010). In contrast failure to identify
loss of parasympathetic integrity is accompanied by dire conse-
quences as witnessed by the 22% increase in sudden death in the
ACCORD study with intensification of therapy (Calles-Escandon
et al., 2010; Pop-Busui et al., 2010). Clearly this is discord rather
than accord.
CONCLUSION
There is now strong evidence of inflammation with activation of
inflammatory cytokines such as IL-6 and leptin in newly diag-
nosed type 2 diabetes. These changes correlate with abnormalities
in sympathetic-vagal balance. Autonomic dysfunction has been
shown to be a predictor of cardiovascular risk and sudden death
in patients with type 2 diabetes. A better understanding of the
autonomic dysfunction and adipose tissue inflammation seen
early in the development of diabetes will lead to further mea-
sures for determining which individuals are at the highest risk
for CVD and mortality, and will also lead to the development of
new therapies for reducing that risk. Activation of the efferent
arm of the reflex arc (through the administration of an acetyl-
choline receptor agonist) causes a decrease in pro-inflammatory
cytokine production, and a reduction in disease severity (Bernik
et al., 2002; Van Maanen et al., 2009). In his review Tracey (2009)
points out a number of important clinical studies that show cor-
relations between vagal nerve activity and inflammatory human
diseases such as rheumatoid arthritis and lupus. Our results are
in keeping with this research, and suggest that such a reflex arc
FIGURE 7 | Restoration of autonomic balance.
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may be involved in the inflammation seen early in T2D. How-
ever, our studies implicate the hypothalamus as the conductor
of the endocrine orchestra and show that the earliest changes
that are detectable in the evolution of diabetes are abnormalities
in autonomic balance (Figure 5). It is not beyond the realms
of reason that we could reverse the unfortunate evolutionary
profile by targeting the hypothalamic set point of autonomic
balance.
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